Eledon Pharmaceuticals To Present At Ladenburg Thalmann Heal...| MENAFN.COM

Sunday, 02 October 2022 09:36 GMT

Eledon Pharmaceuticals To Present At Ladenburg Thalmann Healthcare Conference


(MENAFN- GlobeNewsWire - Nasdaq)

IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 2:00 p.m. ET in New York City.

To register in advance for the fireside chat webcast, sign up here .

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company's website at  .

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at  .

Follow Eledon Pharmaceuticals on social media: LinkedIn ; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047




Tags ALS CD40L eledon IgA Nephropathy Islet cell transplant kidney transplant tegoprubart

MENAFN22092022004107003653ID1104911041


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.